Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Table 5 List of genes differentially expressed between the EGFR exon 19 deletion and exon 21 L858R mutation groups

Gene	Chromosome	Reference base	Mutated base	Mutation frequency			P value^a
Gene	Chromosome	Reference base	Mutated base	EGFR 19 deletion	Exon 21 L858R mutation	Difference	P value^a
EGFR	7	T	–	0	1	1	0.000
PARP1	1	A	G	0.583	0.083	0.5	0.027
SPEN	1	T	C	0.417	0	0.417	0.037
SPEN	1	A	G	0.417	0	0.417	0.037
IGF1R	15	GGT	G	0.417	0	0.417	0.037
NOS3	7	C	G	0.583	0	0.583	0.005
KMT2D	12	G	A	0.417	0	0.417	0.037
IGF1R	15	G	A	0.417	0	0.417	0.037
SUFU	10	G	A	0.583	0.083	0.5	0.027
EP300	22	T	C	0.583	0.083	0.5	0.027
SPEN	1	A	G	0.417	0	0.417	0.037
ACVR1B	12	C	T	0.417	0	0.417	0.037
FLT1	13	T	C	0.417	0	0.417	0.037
IGF1R	15	T	C	0.417	0	0.417	0.037
RARA	17	C	T	0.417	0	0.417	0.037
CSF1R	5	G	A	0.417	0	0.417	0.037
ZC3HAV1	7	G	A	0.417	0	0.417	0.037
NOS3	7	T	G	0.5	0	0.5	0.014
ATG9B	7	G	T	0.583	0.083	0.5	0.027
PARP1	1	C	G	0.583	0.083	0.5	0.027

ISSN: 2523-3548